| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/20/2023 | 168.46% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 08/04/2023 | 168.46% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 06/05/2023 | 168.46% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 05/05/2023 | 168.46% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 03/06/2023 | 168.46% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 08/05/2022 | 168.46% | HC Wainwright & Co. | $12 → $8 | Maintains | Buy |
| 05/06/2022 | 302.68% | HC Wainwright & Co. | $14 → $12 | Maintains | Buy |
| 09/28/2021 | — | Citigroup | Upgrades | Neutral → Buy | |
| 08/06/2021 | 168.46% | Goldman Sachs | $9 → $8 | Maintains | Sell |
| 08/06/2021 | 101.34% | RBC Capital | $13 → $6 | Maintains | Sector Perform |
| 08/10/2020 | 302.68% | Citigroup | $14 → $12 | Maintains | Neutral |
| 08/07/2020 | 235.57% | SVB Leerink | $14 → $10 | Maintains | Market Perform |
| 06/25/2020 | 202.01% | B of A Securities | → $9 | Reinstates | → Underperform |
| 05/20/2020 | 436.91% | Cantor Fitzgerald | $14 → $16 | Maintains | Neutral |
| 12/06/2019 | 403.36% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 10/08/2019 | 168.46% | Goldman Sachs | $24 → $8 | Downgrades | Neutral → Sell |
| 08/09/2019 | 202.01% | Barclays | $21 → $9 | Maintains | Underweight |
| 05/10/2019 | 705.37% | Citigroup | → $24 | Downgrades | Buy → Neutral |
| 05/10/2019 | 571.14% | Cantor Fitzgerald | $57 → $20 | Downgrades | Overweight → Neutral |
| 03/01/2019 | 2248.99% | Citigroup | $67 → $70 | Maintains | Buy |
| 01/17/2019 | — | Leerink Swann | Initiates Coverage On | → Market Perform | |
| 01/03/2019 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 11/19/2018 | 839.6% | Goldman Sachs | $36 → $28 | Upgrades | Sell → Neutral |
| 11/02/2018 | 671.81% | JP Morgan | $83 → $23 | Maintains | Underweight |
| 11/02/2018 | 1577.85% | Cantor Fitzgerald | $75 → $50 | Maintains | Overweight |
| 11/02/2018 | 873.15% | Barclays | $72 → $29 | Downgrades | Equal-Weight → Underweight |
| 11/02/2018 | 671.81% | JP Morgan | $83 → $23 | Downgrades | Overweight → Underweight |
| 10/01/2018 | 2416.78% | Cantor Fitzgerald | → $75 | Initiates Coverage On | → Overweight |
What is the target price for Puma Biotechnology (PBYI)?
The latest price target for Puma Biotechnology (NASDAQ: PBYI) was reported by HC Wainwright & Co. on September 20, 2023. The analyst firm set a price target for $8.00 expecting PBYI to rise to within 12 months (a possible 168.46% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Puma Biotechnology (PBYI)?
The latest analyst rating for Puma Biotechnology (NASDAQ: PBYI) was provided by HC Wainwright & Co., and Puma Biotechnology reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Puma Biotechnology (PBYI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Puma Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Puma Biotechnology was filed on September 20, 2023 so you should expect the next rating to be made available sometime around September 20, 2024.
Is the Analyst Rating Puma Biotechnology (PBYI) correct?
While ratings are subjective and will change, the latest Puma Biotechnology (PBYI) rating was a reiterated with a price target of $0.00 to $8.00. The current price Puma Biotechnology (PBYI) is trading at is $2.98, which is within the analyst's predicted range.